Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: July 2024

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

Posted on July 19, 2024 by MissionIR

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease and Parkinson’s Disease, has released new data from its Phase III study of buntanetap for early Parkinson’s Disease. The study … Continue reading →

Posted in Annovis Bio Inc. ANVS | Leave a comment

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Posted on July 18, 2024 by MissionIR

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and protecting neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), have revealed plans … Continue reading →

Posted in Clene Inc. CLNN | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Reveals Findings of Hyperion Research Quantum Optimization ROI Study and Announces Nomination for Technology Impact Awards

Posted on July 18, 2024 by MissionIR

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the findings of a recent study it commissioned with Hyperion Research on enterprise quantum computing adoption … Continue reading →

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference

Posted on July 17, 2024 by MissionIR

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and … Continue reading →

Posted in Clene Inc. CLNN | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide

Posted on July 17, 2024 by MissionIR

Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. Strong patents covering … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Posted on July 17, 2024 by MissionIR

Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant strides in the field of … Continue reading →

Posted in Annovis Bio Inc. ANVS | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth

Posted on July 16, 2024 by MissionIR

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap

Posted on July 16, 2024 by MissionIR

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced receipt of approval from the U.S. Food and Drug Administration (“FDA”) to transition to … Continue reading →

Posted in Small Cap News | Leave a comment

MissionIRNewsBreaks – Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF) Announces Completion of Business Combination with G Mining Ventures

Posted on July 15, 2024 by MissionIR

Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF), a leading gold explorer in the Guiana Shield, has completed its business combination with G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF). The business combination was completed through a court-approved plan of arrangement under … Continue reading →

Posted in Reunion Gold Corp. RGDFF | Leave a comment

MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology

Posted on July 15, 2024 by MissionIR

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering … Continue reading →

Posted in Nutriband Inc. NTRB | Leave a comment